# Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

> **NCT01420679** · PHASE3 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 21 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Pralatrexate Injection

## Key facts

- **NCT ID:** NCT01420679
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420679, "Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01420679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*